Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.39 |
| ▸ | KCNQ4 | P56696 | 3/20 | 0.37 |
| ▸ | KCNQ5 | Q9NR82 | 3/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.36 |
| ▸ | WNT3A | P56704 | 2/20 | 0.34 |
| ▸ | LDHA | P00338 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PSEN1 | P49768 | 4/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 4/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 4/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 4/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 4/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 4/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5869160 | 0.89 | LDHA (0.37) | TLR9TLR8TLR7CYP17A1LDHA | |
| SCHEMBL5868977 | 0.88 | CYP17A1 (0.39) | TLR9TLR8TLR7KCNQ4KCNQ5 | |
| SCHEMBL5868857 | 0.81 | MAPK13 (0.41) | TLR9TLR8TLR7KCNQ4KCNQ5 | |
| SCHEMBL7459709 | 0.80 | KCNQ4 (0.37) | TLR9TLR8TLR7KCNQ4KCNQ5 | |
| SCHEMBL5868815 | 0.77 | CHEK1 (0.40) | TLR9TLR8TLR7CYP17A1LDHA | |
| SCHEMBL5869050 | 0.75 | ALDH1A1 (0.36) | LMNAMAPTPSEN1PSEN2APH1B | |
| SCHEMBL5868756 | 0.72 | KCNQ4 (0.44) | KCNQ4KCNQ5CYP17A1TDP1LMNA | |
| SCHEMBL5869056 | 0.71 | CYP17A1 (0.44) | TLR9TLR8TLR7KCNQ4KCNQ5 | |
| SCHEMBL5869229 | 0.71 | KCNQ4 (0.39) | TLR9TLR8TLR7KCNQ4KCNQ5 | |
| SCHEMBL5869088 | 0.71 | KCNQ4 (0.40) | KCNQ4KCNQ5GPR142 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7151098-B2 | Glutamate receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2006-12-19 | — | — | US | disclosed |
| US-20060148791-A1 | Glutamate receptor antagonists | ADAM GEO | 2006-07-06 | — | — | US | disclosed |
| US-7018998-B2 | Glutamate receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2006-03-28 | — | — | US | disclosed |
| US-6960578-B2 | Glutamate receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2005-11-01 | — | — | US | disclosed |
| US-20050234048-A1 | Glutamate receptor antagonists | ADAM GEO | 2005-10-20 | — | — | US | disclosed |
| EP-1224175-B1 | BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2004-03-17 | — | — | EP | disclosed |
| US-20030092677-A1 | Glutamate receptor antagonists | ADAM GEO (DE) | 2003-05-15 | — | — | US | disclosed |
| US-6509328-B1 | Metabotropic glutamate receptor antagonists and accordingly are useful for the treatment of a range of neurological disorders, including psychosis, schizophrenia, Alzheimer's and others | HOFFMANN-LA ROCHE INC. | 2003-01-21 | — | — | US | disclosed |
| EP-1224175-A2 | BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001029012-A2 | BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092677-A1 | Glutamate receptor antagonists | GRM1, GRM3, GRM2 | TLR9 1431/4885TLR8 2083/4885TLR7 1151/4885 |
| US-20050234048-A1 | Glutamate receptor antagonists | GRM3, GRM1, GRM2 | TLR9 1302/4885TLR8 1698/4885TLR7 1000/4885 |
| US-20060148791-A1 | Glutamate receptor antagonists | GRM3, GRM1, GRM2 | TLR9 1302/4885TLR8 1698/4885TLR7 1000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.